Trial of Sertraline to Treat Children With Fragile X Syndrome

• Status: Completed
• Trial end date: 2015-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a control trial of sertraline (Zoloft) in fragile X syndrome children aged 2 years to 5 years 8 months old. The trial is six months long, and each participant will receive a series of tests at both the beginning and end of the study. The researchers hope to show improvements in language and a decrease in autistic symptoms.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Randi J. Hagerman, MD; University of California, Davis
• Treatments: Sertraline

Criteria

Inclusion Criteria:

• Fragile X Syndrome

Exclusion Criteria:

• Current or past SSRI treatment

• Current or past MAOI (monoamine oxidase inhibitor ) treatment

• Serious co-morbid medical disorder affecting brain function and behavior (not including fragile X syndrome).

• Uncontrolled seizure disorder or epilepsy

• Bipolar disorder

• Latex allergies